VCM
LENZ

Vivaldi Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Vivaldi Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,052
Closed -$586K – 282
2026
Q1 		$586K Hold
64,052
– – 0.08% 149
2025
Q4 		$1.02M Buy
64,052
+12,300
+24% +$359K 0.14% 104
2025
Q3 		$2.41M Sell
51,752
-7,500
-13% -$276K 0.34% 72
2025
Q2 		$1.74M Hold
59,252
– – 0.26% 81
2025
Q1 		$1.52M Buy
59,252
+3,000
+5% +$73.9K 0.25% 83
2024
Q4 		$1.39M Sell
56,252
-2,500
-4% -$76.2K 0.21% 90
2024
Q3 		$1.39M Hold
58,752
– – 0.41% 56
2024
Q2 		$1.02M Hold
58,752
– – 0.29% 89
2024
Q1 		$924K Buy
+58,752
New +$1.22M 0.27% 89

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Vivaldi Capital Management's LENZ Position: Q2 2026 in Review

Vivaldi Capital Management sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 64,052 shares — an estimated $586K sold.

Vivaldi Capital Management first reported a position in LENZ in Q1 2024 and held it in 9 quarters. The position peaked at $2.41M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Vivaldi Capital Management reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vivaldi Capital Management sold 64,052 LENZ Therapeutics shares in Q2 2026, an estimated $586K.
  • Vivaldi Capital Management first reported a position in LENZ Therapeutics in Q1 2024 and held it in 9 quarters.
  • Vivaldi Capital Management's LENZ Therapeutics position peaked at $2.41M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Vivaldi Capital Management's 13F filing for Q2 2026.